Hemorrhage, Surgical Clinical Trial
Official title:
A Prospective, Multicenter, Single-arm, Clinical Investigation Evaluating the Safety and Performance of GATT-Patch for Hemostasis During Open Liver Surgery
Verified date | April 2022 |
Source | GATT Technologies BV |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the clinical safety and performance of GATT-Patch for management of haemorrhage during elective open liver surgery.
Status | Completed |
Enrollment | 47 |
Est. completion date | February 7, 2022 |
Est. primary completion date | December 7, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Participant is scheduled to undergo an elective open surgery on the liver; - Participant is willing and able to give written informed consent for investigation participation; - Participant is 18 years of age or older at the time of enrollment; - Participant has been informed of the nature of the clinical investigation. A participant must meet all of the following intraoperative inclusion criteria to be treated with the investigational device: - Participant in whom the Investigator is able to identify a target bleeding site at the liver resection plane for which any applicable conventional means for hemostasis (e.g. suture, ligature or cautery) are ineffective or impractical and the choice is made to use a topical hemostat for control of hemostasis; and the choice is made to use a topical hemostat for control of hemostasis; - Participant has a minimal, mild, or moderate target bleeding; Exclusion Criteria: - Participant is scheduled to undergo surgery on other organs besides the liver (e.g. pancreas, colon, lungs); - Participant is taking multiple antithrombotic therapies in therapeutic dosage up to the time of surgery, allowing exclusive use of acetylsalicylic acid; - Participant has platelet count <100 x 10ˆ9/L, an activates partial thrombin time of >100s, or international normalized ratio >2.5; - Participant is pregnant, planning on becoming pregnant or actively breast-feeding during the follow-up period; - Participant has a known hypersensitivity to brilliant blue (FD&C Blue #1); - Participant has an active or suspected infection at the surgical site; - Participant has a total bilirubin level of = 2.5 mg/dl - Participant has had or has planned to receive any organ transplantation; - Participant has American Association of Anesthesiologists (ASA) classification of 4/5; - Participant has a life expectancy of less than 3 months; - Participant has a documented severe congenital or acquired immunodeficiency; - Participant in whom the investigational device will be used at the site of a synthetic graft or patch implant; - Participant is currently participating or has participated in another clinical investigation within the past 30 days that may affect the endpoints of the study, such as trials related to the surgical procedure, and on anti-coagulation; - Participant is not appropriate for inclusion in the clinical investigation, per the medical opinion of the Investigator; - Participant has any incidental (pre- and peri-operative) findings deemed by the Investigator to potentially jeopardize the safety or welfare of the patient |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Groningen | Groningen | |
Netherlands | Radboud University Medical Center | Nijmegen | Gelderland |
Netherlands | Erasmus University Medical Center | Rotterdam | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
GATT Technologies BV | Avania |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Performance of GATT-Patch in achieving hemostasis at 3 minutes | The primary performance endpoint is defined as non-inferiority of GATT-Patch compared to the standard of care regarding the percentage of cases achieving hemostasis at 3 minutes. (i.e. demonstrate GATT-Patch is significantly greater than literature-based performance goal of 65.4 percent). | During procedure | |
Secondary | Mean time to hemostasis (seconds) | The mean time to hemostasis will be calculated based on time to hemostasis determined at 30 seconds intervals. | During procedure | |
Secondary | The number of participants achieving hemostasis at 30, 60, 90, 120 and 150 seconds. | The number of participants achieving hemostasis at 30, 60, 90, 120, and 150 seconds will be determined. | During procedure | |
Secondary | The percentage of participants achieving hemostasis at 30, 60, 90, 120 and 150 seconds. | The percentage of participants achieving hemostasis at 30, 60, 90, 120, and 150 seconds will be determined. | During procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05077124 -
Safe and Timely Antithrombotic Removal (STAR) Registry
|
||
Active, not recruiting |
NCT06114758 -
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
|
||
Recruiting |
NCT05900037 -
GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery
|
N/A | |
Completed |
NCT05397652 -
The Aim of This Study is to Examine the Effect of Intravenously Administered Tranexamic Acid (TXA) on the Visual Clarity, Perioperative Hemorrhage, Duration and Early Postoperative Course of Shoulder Arthroscopy in Beach Chair Position.
|
Phase 4 | |
Not yet recruiting |
NCT02461329 -
Comparison of the Effects of Gelatine Versus Balanced Crystalloid Solution for Volume Therapy
|
N/A | |
Not yet recruiting |
NCT06357455 -
Platelet Count and Function After Usage of Two Different Cell Saver Devices During Liver Transplant Surgery
|
N/A | |
Completed |
NCT06038981 -
Assessment of the Impact of Perioperative Administration of Tranexamic Acid on Bleeding After Sleeve Gastrectomy
|
N/A | |
Terminated |
NCT05093504 -
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
|
N/A | |
Completed |
NCT05385952 -
GATT-Patch Versus TachoSil in Liver Surgery
|
N/A | |
Completed |
NCT04976530 -
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
|
N/A |